Resveratrol solid lipid nanoparticles to trigger credible inhibition of doxorubicin cardiotoxicity

Background: Doxorubicin (DOX), a broad-spectrum chemotherapy drug, is clinically employed to treat cancers especially for breast cancer and lung cancer. But its clinical applications are limited by the dose-dependent cardiac toxicity. Resveratrol (Res), a polyphenolic antitoxin, has been proved to b...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Lili, Zhu, Kexin, Zeng, Hairong, Zhang, Jiaxin, Pu, Yiqiong, Wang, Zhicheng, Zhang, Tong, Wang, Bing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681569/
https://www.ncbi.nlm.nih.gov/pubmed/31534336
http://dx.doi.org/10.2147/IJN.S211130

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681569/
https://www.ncbi.nlm.nih.gov/pubmed/31534336
http://dx.doi.org/10.2147/IJN.S211130

Ejemplares similares